Matthew Rubach
Associate Professor of Medicine
Associate Research Professor of Global Health
Appointment:
Topics:
Countries:
Matthew Rubach
Associate Professor of Medicine
Associate Research Professor of Global Health
Matthew Rubach, MD is a specialist in clinical infectious diseases with medical specialty training in Pediatrics, Internal Medicine and Medical Microbiology. Since November 2015, he has been based full-time as a clinical researcher and clinician in Moshi, Tanzania where he serves as Co-Director of the Kilimanjaro Christian Medical Centre (KCMC)-Duke Health Collaboration. He conducts clinical research on causes of severe febrile illness, sepsis management, vascular pathology of severe malaria, and zoonotic disease epidemiology. In addition to clinical research, he serves as Medical Director of the laboratory that supports clinical investigation at KCMC and he provides medical care & training in the HIV clinic and Medical Ward of KCMC.
His primary appointment is Associate Professor in the Department of Medicine, Division of Infectious Diseases & International Health, with a joint appointment to the Duke Global Health Institute and an adjunct appointment at Duke-National University of Singapore Medical School’s Programme in Emerging Infectious Diseases.
Dr. Rubach holds a Bachelor of Arts from Princeton University. He received his Doctor of Medicine from the University of Arizona, and then went on to complete specialty training in a combined Internal Medicine-Pediatrics residency program at the University of Utah. He completed adult sub-specialty fellowship training in Infectious Diseases at Duke University, followed by a capstone fellowship in Clinical Pathology-Medical Microbiology at the University of Utah. He has board certification from the American Board of Pediatrics (2011-2021) and is actively maintaining his board certifications from the American Board of Internal Medicine (General Medicine and Infectious Diseases) and the American Board of Pathology (Medical Microbiology).
Projects
-
Sepsis Characterization in Kilimanjaro (SICK)
Tanzania
-
Viral Zoonoses and Severe Febrile Illness in northern Tanzania
Tanzania
-
Investigating Febrile Deaths in Tanzania
Tanzania
-
Nitric Oxide and Microvascular Dysfunction in Severe Malaria
Tanzania
-
Molecular Epidemiology of Brucellosis in Northern Tanzania
Tanzania
-
International Maternal Pediatric Adolescent AIDS Clinical Trials
Tanzania
Publications
-
Linster M, Zahari M, Zhuang Y, Mah MG, Carugati M, Moorthy G, et al. Respiratory Pathogen Detection Among Febrile Inpatients in Northern Tanzania, 2016-2019. Open Forum Infect Dis. 2026 Jul;13(7):ofag317.Chia WN, Zhu F, Cheng SMS, Yap WC, Alshukairi AN, Mah YY, et al. Cross-clade vaccination to overcome sarbecovirus or merbecovirus neutralization gaps. Cell Rep. 2026 Jun 23;45(6):117444.Madut DB, Rubach MP, Scheutz F, Call DR, Gogry FA, Carugati M, et al. Population Structure of Escherichia coli Isolated From the Human Bloodstream, Human and Animal Feces, and the Environment in Northern Tanzania. J Infect Dis. 2026 Jan 17;233(1):112–21.Moorthy GS, Blocher BH, Madut DB, Miller HK, Perniciaro JL, Halliday JEB, et al. Antibodies to Tick Salivary Antigens AV422 and Calreticulin in Patients With Spotted Fever Group Rickettsioses and Other Febrile Illnesses in Northern Tanzania. J Infect Dis. 2026 Jan 17;233(1):206–15.
See more publications at Scholars@Duke


